Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study

Inclusion Criteria: * Subjects attending emergency room due to potential HIV exposition of either sex: * Aged 18 years or more. * Who have been exposed to non-occupational HIV and who meet the prerequisites for the current recommendations to begin prophylaxis post-exposition with three antiretroviral drugs. * Who after being fully informed, give their written consent to participate in the study and undergo the tests and examinations required. * Individuals able to do follow up correctly. Exclusion Criteria: * Pregnant women or nursing mothers or women trying to conceive during the study period. * Patients in whom it is known or suspected that the source case has a resistance to one of the drugs from the study treatment regimens. * Treatment with drugs that are contraindicated in the study or products that are in the investigational phase. * Allergic reactions or intolerance to the compounds of the study treatment regiments